Search

Your search keyword '"Schreiber S"' showing total 5,074 results
Start Over Author "Schreiber S"
5,074 results on '"Schreiber S"'

1. Ageing & Sports

Author

Müller P, Ahrens D, Braun-Dullaeus R, and Schreiber S

Subjects
Sports medicine, RC1200-1245
Published
2021
Full Text
View/download PDF

2. Two-color operation of a soft x-ray FEL with alternation of undulator tunes

Author

Schneidmiller, E. A., Macias, I. J. Bermudez, Beye, M., Braune, M., Czwalinna, M. -K., Duesterer, S., Faatz, B., Ivanov, R., Jastrow, F., Kuhlmann, M., Roensch-Schulenburg, J., Schreiber, S., Sorokin, A., Tiedtke, K., Yurkov, M. V., and Zemella, J.

Subjects
Physics - Accelerator Physics, Physics - Instrumentation and Detectors, Physics - Optics
Abstract

FLASH is the first soft X-ray FEL user facility, routinely providing brilliant photon beams for users since 2005. The second undulator branch of this facility, FLASH2, is gap-tunable which allows to test and use advanced lasing concepts. In particular, we developed a two-color operation mode based on the alternatingly tuned undulator segments (every other segment is tuned to the second wavelength). This scheme is advantageous in comparison with a subsequent generation of two colors in two consecutive sections of the undulator line. First, source positions of the two FEL beams are close to each other which makes it easier to focus them on a sample. Second, the amplification is more efficient in this configuration since the segments with respectively "wrong" wavelength still act as bunchers. We studied operation of this scheme in the regime of small and large separation of tunes (up to a factor of two). We developed new methods for online intensity measurements of the two colors simultaneously that require a combination of two detectors. We also demonstrated our capabilities to measure spectral and temporal properties of two pulses with different wavelengths.

Published
2022

3. Recovery time of a plasma-wakefield accelerator

Author

D'Arcy, R., Chappell, J., Beinortaite, J., Diederichs, S., Boyle, G., Foster, B., Garland, M. J., Caminal, P. Gonzalez, Lindstrøm, C. A., Loisch, G., Schreiber, S., Schröder, S., Shalloo, R. J., Thévenet, M., Wesch, S., Wing, M., and Osterhoff, J.

Subjects
Physics - Accelerator Physics
Abstract

The interaction of intense particle bunches with plasma can give rise to plasma wakes capable of sustaining gigavolt-per-metre electric fields, which are orders of magnitude higher than provided by state-of-the-art radio-frequency technology. Plasma wakefields can, therefore, strongly accelerate charged particles and offer the opportunity to reach higher particle energies with smaller and hence more widely available accelerator facilities. However, the luminosity and brilliance demands of high-energy physics and photon science require particle bunches to be accelerated at repetition rates of thousands or even millions per second, which are orders of magnitude higher than demonstrated with plasma-wakefield technology. Here we investigate the upper limit on repetition rates of beam-driven plasma accelerators by measuring the time it takes for the plasma to recover to its initial state after perturbation by a wakefield. The many-nanosecond-level recovery time measured establishes the in-principle attainability of megahertz rates of acceleration in plasmas. The experimental signatures of the perturbation are well described by simulations of a temporally evolving parabolic ion channel, transferring energy from the collapsing wake to the surrounding media. This result establishes that plasma-wakefield modules could be developed as feasible high-repetition-rate energy boosters at current and future particle-physics and photon-science facilities.

Published
2022
Full Text
View/download PDF

4. Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARγ2 P12A polymorphism: a double blind, randomized, controlled cross-over study

Author

Winkler P, Laue C, Auinger A, Pfeuffer M, Häsler R, Helwig U, Rubin D, Herrmann J, Schreiber S, Bell D, and Schrezenmeir J

Subjects
Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background Peroxisome proliferator-activated receptor (PPAR)γ is a key regulator in adipose tissue. The rare variant Pro12Ala of PPARγ2 is associated with a decreased risk of insulin resistance. Being dietary PPARγ ligands, conjugated linoleic acids (CLAs) received considerable attention because of their effects on body composition, cancer, atherosclerosis, diabetes, obesity and inflammation, although some effects were only demonstrated in animal trials and the results in human studies were not always consistent. In the present study effects of CLA supplementation on genome wide gene expression in adipose tissue biopsies from 11 Ala12Ala and 23 Pro12Pro men were investigated. Subjects underwent four intervention periods (4 wk) in a randomized double blind cross-over design receiving 4.25 g/d of either cis-9, trans-11 CLA, trans-10,cis-12 CLA, 1:1 mixture of both isomers or a reference linoleic acid oil preparation. After each intervention biopsies were taken, whole genome expression microarrays were applied, and genes of interest were verified by realtime PCR. Results The following genes of lipid metabolism were regulated by CLA: LDLR, FASN, SCD, FADS1 and UCP2 were induced, while ABCA1, CD36 and CA3 were repressed. Transcription factors PPARγ, NFAT5, CREB5 and EBF1, the adipokine NAMPT, members of the insulin signaling cascade SORBS1 and IGF1 and IL6ST were repressed, while the adipokine THBS1 and GLUT4 involved in insulin signaling were induced. Compared to trans-10,cis-12 CLA and the CLA mixture the cis-9, trans-11 CLA isomer exerted weaker effects. Only CD36 (-1.2 fold) and THBS1 (1.5 fold) were regulated. The CLA effect on expression of PPARγ and leptin genes depends on the PPARγ2 genotype. Conclusion The data suggest that the isomer specific influence of CLA on glucose and lipid metabolism is genotype dependent and at least in part mediated by PPARγ. Trial registration http://www.controlled-trials.com: ISRCTN91188075

Published
2009
Full Text
View/download PDF

5. POS0377 ASSOCIATION OF COMORBIDITIES, MICROBIOTA AND METABOLOMICS WITH ESTABLISHED AND DEVELOPING RHEUMATOID ARTHRITIS

Author

Schirmer, J., primary, Schlicht, K., additional, Demetrowitsch, T., additional, Rohmann, N., additional, Türk, K., additional, Schulte, D., additional, Hartmann, K., additional, Settgast, U., additional, Franke, A., additional, Schwarz, K., additional, Schreiber, S., additional, Hoyer, B. F., additional, and Laudes, M., additional

Published
2024
Full Text
View/download PDF

6. AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS

Author

Deodhar, A., primary, Mc‎ Innes, I. B., additional, Baraliakos, X., additional, Gottlieb, A. B., additional, Kiltz, U., additional, Schreiber, S., additional, Sahoo, B. G., additional, Bao, W., additional, Pricop, L., additional, Gaillez, C., additional, Dong, V., additional, and Mease, P. J., additional

Published
2024
Full Text
View/download PDF

7. BOPfox program for tight-binding and analytic bond-order potential calculations

Author

Hammerschmidt, T., Seiser, B., Ford, M. E., Ladines, A. N., Schreiber, S., Wang, N., Jenke, J., Lysogorskiy, Y., Teijeiro, C., Mrovec, M., Cak, M., Margine, E. R., Pettifor, D. G., and Drautz, R.

Subjects
Physics - Computational Physics, Condensed Matter - Materials Science
Abstract

Bond-order potentials (BOPs) provide a local and physically transparent description of the interatomic interaction. Here we describe the efficient implementation of analytic BOPs in the BOPfox program and library. We discuss the integration of the underlying non-magnetic, collinear-magnetic and noncollinear-magnetic tight-binding models that are evaluated by the analytic BOPs. We summarize the flow of an analytic BOP calculation including the determination of self-returning paths for computing the moments, the self-consistency cycle, the estimation of the band-width from the recursion coefficients, and the termination of the BOP expansion. We discuss the implementation of the calculations of forces, stresses and magnetic torques with analytic BOPs. We show the scaling of analytic BOP calculations with the number of atoms and moments, present options for speeding up the calculations and outline different concepts of parallelisation. In the appendix we compile the implemented equations of the analytic BOP methodology and comments on the implementation. This description should be relevant for other implementations and further developments of analytic bond-order potentials.

Published
2018
Full Text
View/download PDF

8. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

Author

Abreu, M, Ahuja, V, Allez, M, Ananthakrishnan, A, Bemelman, W, Bernstein, C, Braun, J, Chowers, Y, Colombel, J-F, Danese, S, D'Haens, G, D'Hoore, A, Dignass, A, Dotan, I, Dubinsky, M, Ekbom, A, Fleshner, P, Gasche, C, Gassull, MA, Gearry, R, Ghosh, S, Gibson, P, Griffiths, A, Halfvarson, J, Hanauer, S, Harpaz, N, Hart, A, Hibi, T, Kamm, M, Kaplan, G, Kaser, A, Korelitz, B, Kotze, P, Koutroubakis, I, Kruis, W, Lakatos, P, Lewis, J, Lindsay, J, Loftus, E, Louis, E, Lukas, M, Magro, F, Mahadevan, U, Mantzaris, G, Mary, J-Y, McGovern, D, Moum, B, Munkholm, P, Neurath, M, Ng, S, O'Morain, C, Oresland, T, Panaccione, R, Panes, J, Panis, Y, Pemberton, J, Peyrin-Biroulet, L, Prantera, C, Rachmilewitz, D, Ran, Z, Reinisch, W, Remzi, F, Rhodes, J, Riddell, R, Rogler, G, Rubin, D, Sachar, D, Sandborn, W, Sands, B, Sartor, B, Schoelmerich, J, Schreiber, S, Siegel, C, Siegmund, B, Silverberg, M, Söderholm, J, Sood, A, Spinelli, A, Stange, E, Steinwurz, F, Targan, S, Travis, S, Turner, D, Tysk, C, Vatn, M, Vermeire, S, Watanabe, M, Yamamoto, T, Yamamoto-Furusho, J, Ananthakrishnan, Ashwin N, Kaplan, Gilaad G, Bernstein, Charles N, Burke, Kristin E, Lochhead, Paul J, Sasson, Alexa N, Agrawal, Manasi, Tiong, Jimmy Ho Tuan, Steinberg, Joshua, Kruis, Wolfgang, Steinwurz, Flavio, Ahuja, Vineet, Ng, Siew C, Rubin, David T, Colombel, Jean-Frederic, and Gearry, Richard

Published
2022
Full Text
View/download PDF

9. Recovery time of a plasma-wakefield accelerator

Author

D’Arcy, R., Chappell, J., Beinortaite, J., Diederichs, S., Boyle, G., Foster, B., Garland, M. J., Caminal, P. Gonzalez, Lindstrøm, C. A., Loisch, G., Schreiber, S., Schröder, S., Shalloo, R. J., Thévenet, M., Wesch, S., Wing, M., and Osterhoff, J.

Published
2022
Full Text
View/download PDF

10. Navigating the multifaceted intricacies of the Na+-Cl− cotransporter, a highly regulated key effector in the control of hydromineral homeostasis.

Author

Rioux, A. V., Nsimba-Batomene, T. R., Slimani, S., Bergeron, N. A. D., Gravel, M. A. M., Schreiber, S. V., Fiola, M. J., Haydock, L., Garneau, A. P., and Isenring, P.

Subjects
HOMEOSTASIS, ION transport (Biology), MEMBRANE proteins, PRIMATES
Abstract

The Na+-Cl− cotransporter (NCC; SLC12A3) is a highly regulated integral membrane protein that is known to exist as three splice variants in primates. Its primary role in the kidney is to mediate the cosymport of Na+ and Cl− across the apical membrane of the distal convoluted tubule. Through this role and the involvement of other ion transport systems, NCC allows the systemic circulation to reclaim a fraction of the ultrafiltered Na+, K+, Cl−, and Mg+ loads in exchange for Ca2+ and HC O 3 − . The physiological relevance of the Na+-Cl− cotransport mechanism in humans is illustrated by several abnormalities that result from NCC inactivation through the administration of thiazides or in the setting of hereditary disorders. The purpose of the present review is to discuss the molecular mechanisms and overall roles of Na+-Cl− cotransport as the main topics of interest. On reading the narrative proposed, one will realize that the knowledge gained in regard to these themes will continue to progress unrelentingly no matter how refined it has now become. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. First operation of a harmonic lasing self-seeded free electron laser

Author

Schneidmiller, E. A., Faatz, B., Kuhlmann, M., Roensch-Schulenburg, J., Schreiber, S., Tischer, M., and Yurkov, M. V.

Subjects
Physics - Accelerator Physics
Abstract

Harmonic lasing is a perspective mode of operation of X-ray FEL user facilities that allows to provide brilliant beams of higher energy photons for user experiments. Another useful application of harmonic lasing is so called Harmonic Lasing Self-Seeded Free Electron Laser (HLSS FEL) that allows to improve spectral brightness of these facilities. In the past, harmonic lasing has been demonstrated in the FEL oscillators in infrared and visible wavelength ranges, but not in high-gain FELs and not at short wavelengths. In this paper we report on the first evidence of the harmonic lasing and the first operation of the HLSS FEL at the soft X-ray FEL user facility FLASH in the wavelength range between 4.5 nm and 15 nm. Spectral brightness was improved in comparison with Self-Amplified Spontaneous emission (SASE) FEL by a factor of six in the exponential gain regime. A better performance of HLSS FEL with respect to SASE FEL in the post-saturation regime with a tapered undulator was observed as well. The first demonstration of harmonic lasing in a high-gain FEL and at short wavelengths paves the way for a variety of applications of this new operation mode in X-ray FELs.

Published
2016
Full Text
View/download PDF

12. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

Author

Horn, A., Krist, L., Lieb, W., Montellano, F. A., Kohls, M., Haas, K., Gelbrich, G., Bolay-Gehrig, S. J., Morbach, C., Reese, J. P., Störk, S., Fricke, J., Zoller, T., Schmidt, S., Triller, P., Kretzler, L., Rönnefarth, M., Von Kalle, C., Willich, S. N., Kurth, F., Steinbeis, F., Witzenrath, M., Bahmer, T., Hermes, A., Krawczak, M., Reinke, L., Maetzler, C., Franzenburg, J., Enderle, J., Flinspach, A., Vehreschild, J., Schons, M., Illig, T., Anton, G., Ungethüm, K., Finkenberg, B. C., Gehrig, M. T., Savaskan, N., Heuschmann, P. U., Keil, T., and Schreiber, S.

Published
2021
Full Text
View/download PDF

13. X-Ray Science at DESY: Upgrade Programs for the User Facilities FLASH and PETRA III

Author

Baev, K., primary, Bagschik, K., additional, Bartolini, R., additional, Gühr, M., additional, Klumpp, S., additional, Leemans, W., additional, Maier, A. R., additional, Martinez de la Ossa, A., additional, Osterhoff, J., additional, Reichert, H., additional, Schaper, L., additional, Schreiber, S., additional, Schroer, C. G., additional, Schubert, K., additional, Winkler, P., additional, and Weckert, E., additional

Published
2024
Full Text
View/download PDF

18. DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial

Author

Raine, T, primary, Danese, S, additional, Schreiber, S, additional, Gao, X, additional, Hanauer, S, additional, Torres, J, additional, Kligys, K, additional, Huang, X, additional, Neimark, E, additional, Anschutz, T, additional, Crowley, J, additional, and Cross, R K, additional

Published
2024
Full Text
View/download PDF

19. P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases

Author

Danese, S, primary, Colombel, J F, additional, Rieder, F, additional, Peyrin-Biroulet, L, additional, Siegmund, B, additional, Vermeire, S, additional, Dubinsky, M, additional, Schreiber, S, additional, Yarur, A, additional, Panaccione, R, additional, Feagan, B, additional, Mosig, R, additional, Cataldi, F, additional, and Verstockt, B, additional

Published
2024
Full Text
View/download PDF

20. OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

Author

Vermeire, S, primary, Allegretti, J R, additional, Kim, H J, additional, Long, M D, additional, Leszczyszyn, J, additional, Schreiber, S, additional, Mross, M R, additional, Kierkus, J, additional, Peeva, E, additional, Vincent, M S, additional, Shojaee, N, additional, Banfield, C, additional, Banerjee, A, additional, Gale, J D, additional, and Hung, K E, additional

Published
2024
Full Text
View/download PDF

21. P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Author

Panaccione, R, primary, Louis, E, additional, Colombel, J F, additional, D'Haens, G, additional, Peyrin-Biroulet, L, additional, Dubinsky, M, additional, Takeuchi, K, additional, Kalabic, J, additional, Levine, P, additional, Neimark, E, additional, Chen, S, additional, Cheng, L, additional, Duan, W R, additional, Vladea, R, additional, Hecht, P M, additional, Sanchez Gonzalez, Y, additional, Schreiber, S, additional, and Ferrante, M, additional

Published
2024
Full Text
View/download PDF

22. P792 Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study

Author

Bokemeyer, B, primary, Plachta-Danielzik, S, additional, Howaldt, S, additional, Mohl, W, additional, Efken, P, additional, Ehehalt, R, additional, Kahl, M, additional, Krause, T, additional, Trentmann, L, additional, Lügering, A, additional, Schnoy, E, additional, Jochum, C, additional, Fajardo Salmon, S, additional, Hartmann, P, additional, Gilman, E, additional, and Schreiber, S, additional

Published
2024
Full Text
View/download PDF

24. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

Author

Louis, E, primary, Panaccione, R, additional, Parkes, G, additional, Peyrin-Biroulet, L, additional, Ferrante, M, additional, Hisamatsu, T, additional, Siegmund, B, additional, Kalabic, J, additional, Levine, P, additional, Neimark, E, additional, Wallace, K, additional, Chen, S, additional, Cheng, L, additional, Duan, W R, additional, Armuzzi, A, additional, Biederman, L, additional, Loftus, E, additional, Melmed, G, additional, and Schreiber, S, additional

Published
2024
Full Text
View/download PDF

25. P224 JAK-STAT-Driven Tryptophan Degradation Fuels Mucosal Inflammation through QPRT Suppression-Induced Quinolinic Acid Overflow

Author

Welz, L, primary, Kim, N M, additional, Harris, D, additional, Alsaadi, A, additional, Oumari, M, additional, Credidio, G, additional, Taubenheim, J, additional, Tran, F, additional, Sievers, L K, additional, Volk, V, additional, Koncina, E, additional, Verstockt, B, additional, Kaleta, C, additional, Letellier, E, additional, Feuerhake, F, additional, McReynolds, M, additional, Rosenstiel, P, additional, Schreiber, S, additional, and Aden, K, additional

Published
2024
Full Text
View/download PDF

27. N02 Inflammatory bowel disease patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomized controlled trial in Germany (IBDBIO-ASSIST study) - The IBD nurses perspective

Author

Hartmann, P, primary, Zemke, J, additional, Plachta-Danielzik, S, additional, Steiner, I M, additional, Pohlschneider, D, additional, Urzica, E, additional, Tappe, U, additional, Schreiber, S, additional, Steinkat, N, additional, Langbrandtner, J, additional, Hüppe, A, additional, Stargardt, T, additional, and Bokemeyer, B, additional

Published
2024
Full Text
View/download PDF

28. DOP70 Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey

Author

Dubinsky, M C, primary, Gibble, T, additional, Travis, S, additional, Panaccione, R, additional, Hibi, T, additional, Bleakman, A P, additional, Panni, T, additional, Kayhan, C, additional, Favia, A D, additional, Atkinson, C, additional, Schreiber, S, additional, and Rubin, D T, additional

Published
2024
Full Text
View/download PDF

30. P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

Author

Colombel, J F, primary, Hanauer, S B, additional, Sandborn, W J, additional, Sands, B E, additional, Schreiber, S, additional, Danese, S, additional, Kierkus, J, additional, Kulynych, R, additional, Klopocka, M, additional, Lahat, A, additional, Gonciarz, M, additional, Osipenko, M, additional, Borzan, V, additional, Kowalski, M, additional, Saenko, D, additional, Sardinov, R, additional, Lee, S J, additional, Kim, S, additional, Bae, Y, additional, Lee, S, additional, Lee, S G, additional, Yang, S, additional, Lee, J, additional, and Park, G, additional

Published
2024
Full Text
View/download PDF

33. DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Author

Peyrin-Biroulet, L, primary, Bossuyt, P, additional, Regueiro, M, additional, Schreiber, S, additional, Gecse, K, additional, Irving, P, additional, D’Haens, G, additional, Cao, Q, additional, Neimark, E, additional, Huang, X, additional, Anschutz, T, additional, Kligys, K, additional, O’Brien, D, additional, and Panaccione, R, additional

Published
2024
Full Text
View/download PDF

34. P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

Author

Sands, B E, primary, Hanauer, S B, additional, Colombel, J F, additional, Sandborn, W J, additional, Schreiber, S, additional, Danese, S, additional, Klopocka, M, additional, Kulynych, R, additional, Kierkus, J, additional, Soltysiak, A, additional, Smolinski, P, additional, Gonciarz, M, additional, Sreckovic, S, additional, Valuyskikh, E, additional, Horynski, M, additional, Gasbarrini, A, additional, Lee, S J, additional, Kim, S, additional, Bae, Y, additional, Lee, S, additional, Lee, S G, additional, Lee, J H, additional, Kim, J M, additional, and Lee, J, additional

Published
2024
Full Text
View/download PDF

35. OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Sands, B E, primary, Panaccione, R, additional, D'Haens, G, additional, Schreiber, S, additional, DuVall, A, additional, Kierkus, J, additional, Naik, S, additional, Gilder, K, additional, Yun, C, additional, Sandborn, W J, additional, Walczak, M, additional, Vermeire, S, additional, Rubin, D T, additional, Peyrin-Biroulet, L, additional, and Danese, S, additional

Published
2024
Full Text
View/download PDF

36. P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

Author

Feagan Senior Scientific Officer, B G, primary, Matsuoka, K, additional, Rogler, G, additional, Laharie, D, additional, Vermeire, S, additional, Danese, S, additional, Loftus- Jr, E V, additional, Beales, I, additional, Schreiber, S, additional, Kim, H J, additional, Faes, M, additional, Masior, T, additional, Rudolph, C, additional, and Peyrin-Biroulet, L, additional

Published
2024
Full Text
View/download PDF

37. P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study

Author

Sands, B E, primary, Dubinsky, M C, additional, D’Haens, G, additional, Schreiber, S, additional, Danese, S, additional, Hanauer, S B, additional, Kim, D H, additional, Lee, Y N, additional, and Colombel, J F, additional

Published
2024
Full Text
View/download PDF

38. DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

Author

Schreiber, S W, primary, Feagan, B G, additional, Sands, B E, additional, Rieder, F, additional, Torres, J, additional, Liu, Z, additional, Jain, A, additional, Poehler, A M, additional, Wu, H, additional, Osterman, M T, additional, Abreu, M T, additional, and Dulai, P S, additional

Published
2024
Full Text
View/download PDF

40. P285 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: European and US Patient and Health Care Professional Perspectives on the Broad Impact of Bowel Urgency in Ulcerative colitis

Author

Travis, S, primary, Potts Bleakman, A, additional, Panni, T, additional, Schreiber, S, additional, Dubinsky, M, additional, Panaccione, R, additional, Hibi, T, additional, Kayhan, C, additional, Hunter Gibble, T, additional, Flynn, E, additional, Atkinson, C, additional, and Rubin, D T, additional

Published
2024
Full Text
View/download PDF

42. The FLASHForward Facility at DESY

Author

Aschikhin, A., Behrens, C., Bohlen, S., Dale, J., Delbos, N., di Lucchio, L., Elsen, E., Erbe, J. -H., Felber, M., Foster, B., Goldberg, L., Grebenyuk, J., Gruse, J. -N., Hidding, B., Hu, Zhanghu, Karstensen, S., Knetsch, A., Kononenko, O., Libov, V., Ludwig, K., Maier, A. R., de la Ossa, A. Martinez, Mehrling, T., Palmer, C. A. J., Pannek, F., Schaper, L., Schlarb, H., Schmidt, B., Schreiber, S., Schwinkendorf, J. -P., Steel, H., Streeter, M., Tauscher, G., Wacker, V., Weichert, S., Wunderlich, S., Zemella, J., and Osterhoff, J.

Subjects
Physics - Accelerator Physics
Abstract

The FLASHForward project at DESY is a pioneering plasma-wakefield acceleration experiment that aims to produce, in a few centimetres of ionised hydrogen, beams with energy of order GeV that are of quality sufficient to be used in a free-electron laser. The plasma wave will be driven by high-current density electron beams from the FLASH linear accelerator and will explore both external and internal witness-beam injection techniques. The plasma is created by ionising a gas in a gas cell with a multi-TW laser system, which can also be used to provide optical diagnostics of the plasma and electron beams due to the <30 fs synchronisation between the laser and the driving electron beam. The operation parameters of the experiment are discussed, as well as the scientific program., Comment: 19 pages, 9 figures

Published
2015
Full Text
View/download PDF

43. Laser Wire Scanner Compton Scattering Techniques for the Measurement of the Transverse Beam Size of Particle Beams at Future Linear Colliders

Author

Agapov, I., Baleski, K., Blair, G. A., Bosser, J., Braun, H. H., Bravin, E., Boorman, G., Boogert, S. T., Carter, J., D'amico, E., Delerue, N., Howell, D. F., Doebert, S., Driouichi, C., Frisch, J., Hutchins, K. Honkavaaram S., Kamps, T., Lefevre, T., Lewin, H., Paris, T., Poirier, F., Price, M. T., Maccaferi, R., Malton, S., Penn, G., Ross, I. N., Ross, M., Schlarb, H., Schmueser, P., Schreiber, S., Sertore, D., Walker, N., Wendt, M., and Wittenburg, K.

Subjects
Physics - Accelerator Physics
Abstract

This archive summarizes a working paper and conference proceedings related to laser wire scanner development for the Future Linear Collider (FLC) in the years 2001 to 2006. In particular the design, setup and data taking for the laser wire experiments at PETRA II and CT2 are described. The material is focused on the activities undertaken by Royal Holloway University of London (RHUL)., Comment: 61 pages

Published
2014

44. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).

Author

Kucharzik, T., Dignass, A., Atreya, R., Bokemeyer, B., Esters, P., Herrlinger, K., Kannengiesser, K., Kienle, P., Langhorst, J., Lügering, A., Schreiber, S., Stallmach, A., Stein, J., Sturm, A., Teich, N., Siegmund, B., Andus, T., Autschbach, F., Bachmann, O., and Baretton, G.

Published
2024
Full Text
View/download PDF

46. The FLASHForward facility at DESY

Author

Aschikhin, A, Behrens, C, Bohlen, S, Dale, J, Delbos, N, Di Lucchio, L, Elsen, E, Erbe, JH, Felber, M, Foster, B, Goldberg, L, Grebenyuk, J, Gruse, JN, Hidding, B, Hu, Z, Karstensen, S, Knetsch, A, Kononenko, O, Libov, V, Ludwig, K, Maier, AR, Martinez De La Ossa, A, Mehrling, T, Palmer, CAJ, Pannek, F, Schaper, L, Schlarb, H, Schmidt, B, Schreiber, S, Schwinkendorf, JP, Steel, H, Streeter, M, Tauscher, G, Wacker, V, Weichert, S, Wunderlich, S, Zemella, J, and Osterhoff, J

Subjects
Plasma, Wakefield, Acceleration, Beam line, Spectrometer, physics.acc-ph, Nuclear & Particles Physics, Atomic, Molecular, Nuclear, Particle and Plasma Physics, Other Physical Sciences, Astronomical and Space Sciences, Atomic, Molecular, Nuclear, Particle and Plasma Physics
Abstract

The FLASHForward project at DESY is a pioneering plasma-wakefield acceleration experiment that aims to produce, in a few centimetres of ionised hydrogen, beams with energy of order GeV that are of quality sufficient to be used in a free-electron laser. The plasma is created by ionising a gas in a gas cell with a multi-TW laser system. The plasma wave will be driven by high-current-density electron beams from the FLASH linear accelerator. The laser system can also be used to provide optical diagnostics of the plasma and electron beams due to the

Published
2016

47. Experimental demonstration of novel beam characterization using a polarizable X-band transverse deflection structure

Author

Marchetti, B., Grudiev, A., Craievich, P., Assmann, R., Braun, H.-H., Catalan Lasheras, N., Christie, F., D’Arcy, R., Fortunati, R., Ganter, R., González Caminal, P., Hoffmann, M., Huening, M., Jaster-Merz, S. M., Jonas, R., Marcellini, F., Marx, D., McMonagle, G., Osterhoff, J., Pedrozzi, M., Prat Costa, E., Reiche, S., Reukauff, M., Schreiber, S., Tews, G., Vogt, M., Wesch, S., and Wuensch, W.

Published
2021
Full Text
View/download PDF

50. Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial

Author

Schreiber, S., additional, Lee, S., additional, Van der Woude, C. J., additional, Marín-Jiménez, I., additional, Wolf, D., additional, Schnoy, E., additional, Salzberg, B., additional, Busse, C., additional, Nazar, M., additional, Langholff, W., additional, Borghorst, S., additional, Gasink, C., additional, Baker, T., additional, Godwin, B., additional, and Feagan, B., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results